{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:21:11Z","timestamp":1648858871769},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2009,5,1]],"date-time":"2009-05-01T00:00:00Z","timestamp":1241136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2009,5]]},"DOI":"10.1016\/j.leukres.2008.10.021","type":"journal-article","created":{"date-parts":[[2008,12,5]],"date-time":"2008-12-05T10:41:25Z","timestamp":1228473685000},"page":"605-606","source":"Crossref","is-referenced-by-count":1,"title":["Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?"],"prefix":"10.1016","volume":"33","author":[{"given":"Edgar","family":"Faber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.10.021_bib1","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.10.021_bib2","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmakokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients","volume":"22","author":"Peng","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.10.021_bib3","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.021_bib4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-008-0730-x","article-title":"Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults","volume":"63","author":"Menon-Andersen","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.leukres.2008.10.021_bib5","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.leukres.2006.05.019","article-title":"Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)","volume":"31","author":"Horikoshi","year":"2007","journal-title":"Leukemia Res"},{"key":"10.1016\/j.leukres.2008.10.021_bib6","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2003-11-3800","article-title":"High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia","volume":"103","author":"Kantarjian","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.10.021_bib7","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600mg\/day of imatinib as initial therapy","volume":"15","author":"Hughes","year":"2008","journal-title":"Blood"},{"issue":"s1","key":"10.1016\/j.leukres.2008.10.021_bib8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"A prospective randomized study of imatinib 400mg vs 800mg as a frontline therapy in Sokal high risk (HR) Ph-pos chronic myeloid leukemia (CML) patients","volume":"93","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.021_bib9","first-page":"227","article-title":"Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"88","author":"Marin","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2008.10.021_bib10","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1080\/10428190600565057","article-title":"Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing","volume":"47","author":"Faber","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.leukres.2008.10.021_bib11","doi-asserted-by":"crossref","unstructured":"Breccia M, Cannella L, Stefanizzi C, Santopietro M, De Cuia R, Diverio D, Alimena G. Achievement of complete molecular responses in late chronic phase chronic myeloid leukemia patients treated with pulsed imatinib while in minimal residual disease. Leukemia Res 2008.","DOI":"10.1016\/j.leukres.2008.10.024"},{"key":"10.1016\/j.leukres.2008.10.021_bib12","doi-asserted-by":"crossref","unstructured":"Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, et al. for the GIMEMA Working Party on Chronic Myeloid Leukemia. Imatinib and pegylated human recombinant interferon-a2b in early chronic-phase chronic myeloid leukemia. Blood 2004;104:4245\u20134251.","DOI":"10.1182\/blood-2004-03-0826"},{"key":"10.1016\/j.leukres.2008.10.021_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/leu.2008.94","article-title":"Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation","volume":"22","author":"Carella","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2008.10.021_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00277-008-0589-2","article-title":"Efficacy of low-dose imatinib in chronic-phase chronic myelogenous leukemia patients","volume":"88","author":"Kobayashi","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.leukres.2008.10.021_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00277-007-0326-2","article-title":"Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission","volume":"86","author":"Carella","year":"2007","journal-title":"Ann Hematol"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004852?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608004852?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,15]],"date-time":"2019-05-15T21:01:19Z","timestamp":1557954079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608004852"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,5]]}},"alternative-id":["S0145212608004852"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.10.021","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2009,5]]}}}